Immix Biopharma (IMMX) Corporate presentation summary

Unmet medical need in AL amyloidosis

• Over 30,000 U.S. patients with relapsed/refractory AL amyloidosis lack FDA-approved therapies, facing poor outcomes and limited options after frontline treatment failure.

• Standard of care yields only a 0-10% complete response rate in relapsed/refractory settings, with most patients requiring second-line therapy within a year.

NXC-201: Mechanism and innovation

• NXC-201 is a BCMA-targeted CAR-T cell therapy designed to eliminate dysfunctional plasma cells producing toxic light chains.

• Proprietary engineering optimizes cytotoxicity, reduces non-specific activation, and minimizes cytokine release, aiming for safer and more effective treatment.

Clinical trial results and efficacy

• In the U.S. NEXICART-2 trial, NXC-201 achieved a 95% complete response rate in relapsed/refractory AL amyloidosis, with rapid normalization of disease markers and 100% organ response in evaluable patients.

• Responses were observed within the first week for most patients, and the complete response rate improved over time as more data matured.